Equity Income Fund update, June 2017

Important Information

We want to make investing with us simple and straightforward for all of our clients.

Please select your investor type from the options below.

Alternatively you can register or log in to an existing account.

Please note that by making your selection here you are agreeing to the Woodford Investment Management Ltd Privacy Statement and to our Terms and Conditions.

Mitchell Fraser-Jones 14 July 2017 Est. reading: 6 min read

Home > Words > Insights > Equity Income Fund update, June 2017

Having enjoyed a strong run in the first five months of 2017, equity markets came under pressure in June. This was partly the result of conflicting messages emanating from the major central banks.

Following the Federal Reserve’s second rate rise this year and more hawkish tones from other central banks, the market is now worrying about a more widespread tightening of monetary policy. There appears to be some confusion among central bankers about the causes of current levels of inflation and how long they may be expected to last. In our view, there is no evidence of sustained inflation at present. Indeed, we are still more concerned about the prospect of deflation once the current bout of temporary, commodity-price related (and, in the case of the UK, currency-related) inflation washes through the system. The ultra-low interest rates that have been in place for so long now have failed to take inflation sustainably back to the 2% rate targeted by policymakers. This suggests that, if anything, even lower rates may be needed to deliver monetary policymakers’ objectives. Nevertheless, the mixed messages emanating from the central banks have prompted more volatile conditions for equity markets.

Against this backdrop, the fund delivered a marginally negative return but outperformed the broader market.

The largest contribution to return came from Capita. The outsourcing company’s shares were boosted by a positive trading update, which underscored the work that its management team has been doing to get the company back on track. Also, towards the end of the month, Capita completed the sale of its asset services division for a much better price than the market had expected. This reduces both the pressure on its balance sheet and the fears that a rights issue will be needed. It will take time for the company to complete its turnaround, but we are encouraged that its management is making good progress. In the meantime, with an estimated yield of almost 5% for 2017, its valuation is still very attractive.

Logistics group Stobart performed well too. Its shares continued to climb higher following the excellent set of full-year results reported in May. In particular, the company’s decision to rebase its dividend payments upwards highlights the valuation attraction of this business which is working hard to realise shareholder value from its collection of assets.

Elsewhere, AbbVie, Prothena and Theravance Biopharma also performed well, benefiting from a broader rally in the US biotechnology sector. This is of course a sector that has been subject to some sharp swings in sentiment over the last couple of years and, although it is difficult to fathom exactly what has driven the recent pick-up in share prices, it has been helpful to short-term performance. The market has exhibited a fickle tendency towards the sector as a whole, so it is worth reminding investors that our interest in the sector is focused on the specific and compelling attractions of individual biotechnology companies. Their return to form in recent weeks is pleasing but it is a drop in the ocean when compared to the long-term potential that they hold.

Meanwhile, the largest detractor from performance was Provident Financial. During the month, the company issued a profit warning related to its consumer credit division. This was due to the reorganisation of its doorstep-lending business, which has involved bringing its self-employed agents in-house. The process is largely complete and should prove highly beneficial for the business in the medium and long-term as it will enable Provident Financial to better manage customer relationships, improve debt collection and drive higher profits in the future. However, the disruption to trading caused by the departure of agents which were not taken on as full-time employees has been greater than management had previously anticipated.

Although this is clearly not helpful, more often than not, the market over-reacts in response to bad news, even if the causes are only transitory. We believe this to be the case here – it doesn’t disrupt the long-term investment case, in our view. Although Provident Financial’s consumer credit division is normally stable and highly cash generative, the real business growth drivers exist elsewhere in the group – Vanquis Bank, Moneybarn and Satsuma all continue to perform very well. Therefore, we believe that Provident’s dividend is unlikely to be affected by this temporary event and the long-term attractions of the group remain very much in place.

Next was also weak, along with the broader UK retail sector. This has been the result of lingering concerns about the outlook for the UK consumer economy. As regular readers will know, we believe the market has become far too pessimistic about the prospects of the domestic economy and although this has weighed on the share prices of businesses like Next, a compelling and contrarian opportunity has, in our view, opened up. As far as Next is concerned, this view was reinforced during the month following a meeting with Lord Wolfson, the company’s CEO, which reassured us that the company remains a well-managed retailer, determined and well-situated to deliver long-term shareholder value. We added to the holding during the month.

Elsewhere in terms of portfolio activity, we increased the positions in a number of other domestically-focused stocks including Barratt Developments, British Land, Taylor Wimpey and Lloyds – again reflecting our more positive view of the UK economy. We also took advantage of share price weakness to add to the fund’s position in Provident Financial.

Furthermore, we introduced two new, albeit small holdings. One of them is Morses Club – a very cash generative business that provides unsecured, short-term loans to its customers. Also, we participated in a funding round for unquoted technology company, Drayson Technologies which is an innovative early-stage company with a range of technologies focused on the ‘internet of things’ and digital health.

To fund the above purchases, we completely sold the fund’s position in British American Tobacco which has been present in the portfolio since its inception and has been a part of Neil’s mandates practically throughout his career. Neil owned stakes in tobacco companies before the dot.com bubble of the late nineties, but it was that episode of market history that marked a significant increase in tobacco exposure which has prevailed until recently. During the bubble, old economy stocks like British American Tobacco became completely unloved by the market – at the peak of the dot.com bubble in March 2000, you could have bought shares in British American Tobacco for just £2.25 per share. We have recently disposed of the holding at over £50 per share.

Over the last twenty years, tobacco has been the best performing sector in the UK stock market as a combination of dividend income, dividend growth and, over time, a re-rating to more appropriate valuation territory, resulted in material capital appreciation for investors and an even more substantial total return. We still retain some exposure to tobacco through Imperial Brands, which remains undervalued in our view, but the valuation opportunity elsewhere in the sector has largely played out. We have evolved the portfolio towards other areas of the stockmarket which we believe can deliver more attractive long-term returns to shareholders.

Overall, the portfolio reflects our caution on the global economic outlook and our growing confidence in the prospects of the UK economy. The result is a mix of high quality, attractively-valued dependable growth companies, a selection of compellingly undervalued domestic cyclical stocks and a collection of earlier-stage businesses which have incredible long-term growth potential. All of these positions can contribute meaningfully to performance and we remain very confident in the fund’s ability to deliver attractively positive long-term returns.

CF Woodford Equity Income Fund
Download as a PDF

What are the risks?

  • The value of the fund and any income from it may go down as well as up, so you may get back less than you invested
  • Past performance cannot be relied upon as a guide to future performance
  • The annual management charge is charged to capital, so the income of the fund may be higher but capital growth may be restricted or capital may be eroded
  • The fund may invest in other transferable securities, money market instruments, warrants, collective investment schemes and deposits
  • The fund may invest in overseas securities and be exposed to currencies other than pound sterling
  • The fund may invest in unquoted securities, which may be less liquid and more difficult to realise than publicly traded securities

Important information

Before investing, you should read the Key Investor Information Document (KIID) for the fund, and the Prospectus which, along with our terms and conditions, can be obtained from the downloads page or from our registered office. If you have a financial adviser, you should seek their advice before investing. Woodford Investment Management Ltd is not authorised to provide investment advice.

Woodford Investment Management Ltd is authorised and regulated by the Financial Conduct Authority (firm reference number 745433). Incorporated in England and Wales, company number 10118169. Registered address 9400 Garsington Road, Oxford OX4 2HN.

Woodford Patient Capital Trust plc is incorporated in England and Wales, company number 09405653. Registered as an investment company under section 833 of the Companies Act 2006. Registered address 40 Dukes Place, London EC3A 7NH.

The Woodford Funds (Ireland) ICAV (the “Fund”) has appointed as Swiss Representative Oligo Swiss Fund Services SA, Av. Villamont 17, 1005 Lausanne, Switzerland, Tel: +41 21 311 17 77, email: info@oligofunds.ch. The Fund’s Swiss paying agent is Neue Helvetische Bank AG. All fund documentation including, Prospectus, Key Investor Information Documents, Instrument of Incorporation and financial reports may be obtained free of charge from the Swiss Representative in Lausanne. The place of performance and jurisdiction for all shares distributed in or from Switzerland is at the registered office of the Swiss Representative. Fund prices can be found at www.fundinfo.com.

© 2017 Woodford Investment Management Ltd.
All rights reserved.

By using this website you are automatically agreeing to the Woodford Investment Management Ltd privacy statement